Innovative Targeting Solutions Inc. (ITS) is engaged in the discovery of next generation biologics using a novel, proprietary, protein engineering technology. ITS’ technology is unlike any existing approach to making fully human mAbs and other biologics. ITS’ platform, because it exploits the human V(D)J recombination system, is capable of “de novo” antibody generation; and, for the first time, allows for mammalian display repertoires of >10^9 to be exploited effectively. This represents a significant advance in display technologies and offers advantages over existing protein engineering approaches; unlike phage or yeast display, reformatting is not required, engineering can take place within the final scaffold, reporter assays and selection strategies can be engineered into the host cell allowing for upfront functional screens.